



Review

The role of mutation of metabolism-related genes in genomic hypermethylation



Joshua J. Waterfall¹, J. Keith Killian¹, Paul S. Meltzer^{*}

Genetics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA

ARTICLE INFO

Article history:

Received 2 June 2014

Available online 8 August 2014

Keywords:

DNA methylation

Metabolism

Cancer

IDH

SDH

FH

ABSTRACT

Genetic mutations, metabolic dysfunction, and epigenetic misregulation are commonly considered to play distinct roles in tumor development and maintenance. However, intimate relationships between these mechanisms are now emerging. In particular, mutations in genes for the core metabolic enzymes IDH, SDH, and FH are significant drivers of diverse tumor types. In each case, the resultant accumulation of particular metabolites inhibits TET enzymes responsible for oxidizing 5-methylcytosine, leading to pervasive DNA hypermethylation.

© 2014 Published by Elsevier Inc.

Contents

1. Introduction	16
2. Discovery of IDH mutations	17
3. IDH mutants produce 2-hydroxyglutarate	18
4. IDH mutant tumors have genomic hypermethylation	18
5. Inhibition of α KG-dependent dioxygenases	19
6. IDH mutations in cancer	19
7. SDH	20
8. SDH mutations in cancer	20
9. SDH mutant tumors have genomic hypermethylation	20
10. FH mutations in cancer	20
11. Conclusion	21
Acknowledgments	21
References	21

1. Introduction

Pioneering work in the first half of the twentieth century established many of the core steps in human metabolism including the tricarboxylic (TCA) or Krebs cycle through which sugars, amino acids, and fatty acids are broken down to produce chemical energy

^{*} Corresponding author. Address: National Cancer Institute, 37 Convent Dr., Bethesda, MD 20892-4265, USA.

E-mail address: pmeltzer@mail.nih.gov (P.S. Meltzer).

¹ Equal contribution.

and molecular building blocks [1]. In the 1950s Otto Warburg discovered that cancer cells have a characteristic type of metabolism, with a high rate of glycolysis despite elevated oxygen levels, and argued that this metabolic shift (the “Warburg effect”) is in fact the central cause of cancer [2]. While the relative contributions to tumorigenesis of metabolism, genetic mutation, and epigenetic misregulation have sometimes been debated, new findings in multiple tumor types have shown the three to be intimately related. Certain malignancies arising in hematopoietic, mesenchymal, neural, as well as epithelial tissues share the common quality that mutations in genes coding for core metabolic proteins drive the




Fig. 1. Epigenomic relatedness of IDH/SDH/FH mutant- versus non-mutant- tumors, as shown by PCA plots and heatmap of DNA methylation profiles. Samples included here are: (1) IDH-mutant versus -wildtype cholangiocarcinoma (GSE49656, $n = 32$; GSE32286, $n = 50$), IDH-mutant versus -wildtype glioma (GSE36278, $n = 136$; GSE48461, $n = 56$; GSE32286, $n = 62$) and IDH-mutant versus -wildtype chondrosarcoma (GSE40853, $n = 51$); (2) SDHx- versus kinase-mutant GIST (GSE34387, $n = 69$) and SDHx- versus kinase-mutant paraganglioma/pheochromocytoma (GSE43293, $n = 22$); and (3) multiple normal associated tissue lineages ($n = 19$). (Sample color legends shown in PCA plots also correspond to heatmap colorbars.) Variables included here are the CpG methylation β -values, as measured by Infinium 450 K array, of the top 10 K differentially-methylated CpG targets between IDH/SDH/FH mutant- and non-mutant tumor groups (statistical calculations and graphics performed with QIucore Omics Explorer software). In general, IDH/SDH/FH mutant tumors of diverse histological types and embryonic lineages show significantly greater global DNA hypermethylation than non-mutant counterparts.

accumulation of DNA hypermethylation (Fig. 1). While much remains to be learned about these phenomena, the recurrent reconciliation of these distinct pathways across such diverse tumor types provides new insights into oncogenic mechanisms and tumor biology.

2. Discovery of IDH mutations

One of the most unanticipated discoveries of the early genome wide cancer mutation profiling efforts was the report of recurrent somatic mutations in the *IDH1* gene. In 2008 and 2009 recurrent

Download English Version:

<https://daneshyari.com/en/article/1928339>

Download Persian Version:

<https://daneshyari.com/article/1928339>

[Daneshyari.com](https://daneshyari.com)